An innovative outcome-based care and procurement model of hemophilia management

References

• Mannucci PM, Tuddenham EGD. The hemophilias: progress and problems. Semin Hematol. 1999;36:104–117.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–e47.
   PubMed Web of Science ®Google Scholar
• Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010;8:1895–1902.
   PubMed Web of Science ®Google Scholar
• Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125:2038–2044.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20:459–463.
   PubMed Web of Science ®Google Scholar
• Nijdam A, Kurnik K, Liesner R, et al. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia. 2015;21:444–450.
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25–32.
   PubMed Web of Science ®Google Scholar
• Funk MB, Schmidt H, Becker S, et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia. 2002;8:98–103.
   PubMed Web of Science ®Google Scholar
• Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus. 2012;10:169–173.
   PubMed Web of Science ®Google Scholar
• Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia. 2002;8:753–760.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Kraft J, Blanchette V, Babyn P, et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia a treated with tailored primary prophylaxis in Canada. J Thromb Haemost. 2012;10:2494–2502.
   PubMed Web of Science ®Google Scholar
• Funk M, Schmidt H, Escuriola-Ettingshausen C, et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol. 1998;77:171–174.
   PubMed Web of Science ®Google Scholar
• den Uijl IEM, de Schepper AMA, Camerlinck M, et al. Magnetic resonance imaging in teenagers and young adults with limited haemophilic arthropathy: baseline results from a prospective study. Haemophilia. 2011;17:926–930.
   PubMed Web of Science ®Google Scholar
• Sørensen B, Auerswald G, Benson G, et al. Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis. 2015;26:849–857.
   PubMed Web of Science ®Google Scholar
• Ar MC, Vaide I, Berntorp E, et al. Methods for individualising factor VIII dosing in prophylaxis. Eur J Haematol. 2014;93(Suppl 76):16–20.
   Web of Science ®Google Scholar
• Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20:607–615.
   PubMed Web of Science ®Google Scholar
• McCarthy M. Obama seeks $213m to fund “precision medicine”. BMJ. 2015;350:h587.
   Google Scholar
• Awad AG. ‘The patient’: at the center of patient-reported outcomes. Expert Rev Pharmacoecon Outcomes Res. 2015;15:729–731.
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Graham CN, McDade CL, et al. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015;21:310–319.
   PubMed Web of Science ®Google Scholar
• Escobar MA. Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia. 2010;16(Suppl 3):29–34.
   PubMed Web of Science ®Google Scholar
• Risebrough N, Oh P, Blanchette V, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia. 2008 Jul;14(4):743–752.
   PubMed Web of Science ®Google Scholar
• Farrugia A, Cassar J, Kimber MC, et al. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013;19:e228–e238.
   PubMed Web of Science ®Google Scholar
• Neufeld EJ, Recht M, Sabio H, et al. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value Health. 2012;15:916–925.
   PubMed Web of Science ®Google Scholar
• Valente M, Cortesi PA, Lassandro G, et al. Health economic models in hemophilia A and utility assumptions from a clinician’s perspective. Pediatr Blood Cancer. 2015;62:1826–1831.
   PubMed Web of Science ®Google Scholar
• Skinner MW. WFH: closing the global gap - achieving optimal care. Haemophilia. 2012;18(Suppl 4):1–12.
   PubMed Web of Science ®Google Scholar
• Unim B, Veneziano MA, Boccia A, et al. Pharmacoeconomic review of prophylaxis treatment versus on-demand. ScientificWorldJournal. 2015;2015:596164.
   PubMedGoogle Scholar
• United Kingdom Haemophilia Centre Director’s Organisation. Bleeding disorder statistics for April 2011 to March 2012: a report from the Natinal Haemohilia Database. Vol. 87. United Kingdom Haemophilia Centre Director’s Organisation (UKHCDO); 2012. Available from: http://www.ukhcdo.org/docs/AnnualReports/2012/1UK%20National%20Haemophilia%20Database%20Bleeding%20Disorder%20Statistics%202011-2012%20for%20website.pdf
   Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10:359–367.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11:1119–1127.
   PubMed Web of Science ®Google Scholar
• Schneider U. Double moral hazard and outcome-based remuneration of physicians. Working Paper 022. Bavarian Graduate Program in Econmoics (BGPE); 2007. Available from: http://www.bgpe.de/texte/DP/022_schneider.pdf
   Google Scholar
• Carlsson M, Berntorp E, Björkman S, et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia. 1997;3:96–101.
   PubMed Web of Science ®Google Scholar
• Brown SA, Phillips J, Barnes C, et al. Challenges in haemophilia care in Australia and New Zealand. Curr Med Res Opin. 2015;31:1985–1991.
   PubMed Web of Science ®Google Scholar
• Antunes SV, Tangada S, Phillips J, et al. Comparison of historic on-demand and prophylaxis bleeding episodes in hemophilia A and B patients with inhibitors treated with FEIBA NF. Haemophilia. 2014;20(Suppl 3):96.
   Google Scholar
• Berntorp E, Spotts G, Patrone L, et al. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics. 2014;2014:115–127.
   Google Scholar
• Pollmann H, Klamroth R, Vidovic N, et al. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study. Ann Hematol. 2013;92:689–698.
   PubMed Web of Science ®Google Scholar
• Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol. 2012;88:329–335.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, Von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700–710.
   PubMed Web of Science ®Google Scholar
• Petrini P, Valentino LA, Gringeri A, et al. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8:237–246.
   PubMed Web of Science ®Google Scholar
• Ahnström J, Berntorp E, Lindvall K, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10:689–697.
   PubMed Web of Science ®Google Scholar
• Fernandes S, Carvalho M, Lopes M, et al. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. Semin Thromb Hemost. 2014;40:785–789.
   PubMed Web of Science ®Google Scholar
• Abshire T. An approach to target joint bleeding in hemophilia: prophylaxis for all or individualized treatment? J Pediatr. 2004;145:581–583.
   PubMed Web of Science ®Google Scholar
• Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308:1452–1459.
   PubMed Web of Science ®Google Scholar
• O’Mahony B, Kent A, Ayme S. Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress: changing the policy landscape: haemophilia patient involvement in healthcare decision-making Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress: changing the policy landscape: haemophilia patient involvement in healthcare decision-making. Eur J Haematol. 2014;92(Suppl 74):1–8.
   PubMed Web of Science ®Google Scholar
• Croteau SE, Padula M, Quint K, et al. Center-based quality initiative targets youth preparedness for medical independence: HEMO-milestones tool in a comprehensive hemophilia clinic setting. Pediatr Blood Cancer. 2016 Mar;63(3):499–503.
   PubMed Web of Science ®Google Scholar
• Reininger AJ, Chehadeh HE. The principles of PK-tailored prophylaxis. Hamostaseologie. 2013;33(Suppl 1):S32–S35.
   PubMed Web of Science ®Google Scholar
• Collins PW. Personalized prophylaxis. Haemophilia. 2012;18(Suppl 4):131–135.
   PubMed Web of Science ®Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–275.
   PubMed Web of Science ®Google Scholar
• Miners AH. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia. 2013;19:174–180.
   PubMed Web of Science ®Google Scholar
• Coppola A, Morfini M, Cimino E, et al. Current and evolving features in the clinical management of haemophilia. Blood Transfus. 2014;12(Suppl 3):S554–S562.
   Google Scholar
• Iem DU, Fischer K, Halimeh S, et al. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis. Thromb Haemost. 2008;99:965–968.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Cortesi P, Iannazzo S, et al. PK-driven prophylaxis using MyPKFiT vs. standard prophylaxis in haemophilia A: a cost-effectiveness analysis. Poster: presented at (EAHAD); 2016 February 3–5; Malmö, Sweden.
   Google Scholar
• Geraghty S, Dunkley T, Harrington C, et al. Practice patterns in haemophilia A therapy – global progress towards optimal care. Haemophilia. 2006;12:75–81.
   PubMed Web of Science ®Google Scholar
• Duncan NA, Kronenberger WG, Krishnan S, et al. Adherence to prophylactic treatment in hemophilia as measured using thre VERITAS-Pro and annual bleed rate (ABR). Value Health. 2014;17(3):A230.
   Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost. 2009;7:413–420.
   PubMed Web of Science ®Google Scholar
• Petrini P, Seuser A. Haemophilia care in adolescents–compliance and lifestyle issues. Haemophilia. 2009;15(Suppl 1):15–19.
   PubMed Web of Science ®Google Scholar
• Zappa S, McDaniel M, Marandola J, et al. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia. 2012;18:e140–e153.
   PubMed Web of Science ®Google Scholar
• Quon D, Reding M, Guelcher C, et al. Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia. Am J Hematol. 2015;90(Suppl 2):S17–S22.
   Google Scholar
• O’Mahony B, Skinner MW, Noone D, et al. Assessments of outcome in haemophilia - a patient perspective. Haemophilia. 2016 Mar 14. doi:10.1111/hae.12922. [Epub ahead of print]
   PubMedGoogle Scholar
• Hay CRM. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia. 2013;19:660–667.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Kurnik K, Huth-Kuhne A, et al. AHEAD. Advate in HaEmophilia A outcome database. Hamostaseologie. 2010;30:S23–S25.
   Google Scholar
• Iorio A, Marcucci M, Cheng J, et al. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. Haemophilia. 2014;20:777–783.
   PubMed Web of Science ®Google Scholar
• Klamroth R, Pollmann H, Hermans C, et al. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia. 2011;17:412–421.
   PubMed Web of Science ®Google Scholar
• Richards M, Altisent C, Batorova A, et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia. 2007;13:473–479.
   PubMed Web of Science ®Google Scholar
• Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17:2–10.
   PubMed Web of Science ®Google Scholar
• Feldman BM, Berger K, Bohn R, et al. Haemophilia prophylaxis: how can we justify the costs? Haemophilia. 2012;18:680–684.
   PubMed Web of Science ®Google Scholar
• Fischer K, Pouw ME, Lewandowski D, et al. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica. 2011;96:738–743.
   PubMed Web of Science ®Google Scholar
• De Moerloose P, Arnberg D, O’Mahony B, et al. Improving haemophilia patient care through sharing best practice. Eur J Haematol. 2015;95(Suppl 79):1–8.
   PubMed Web of Science ®Google Scholar
• Nijdam A, Bladen M, Hubert N, et al. Using routine haemophilia joint health score for international comparisons of haemophilia outcome: standardization is needed. Haemophilia. 2016;22(1):142–147. doi:10.1111/hae.12755.
   Google Scholar
• Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014;95:265–268.
   PubMed Web of Science ®Google Scholar
• Amerine LB, Chen SL, Daniels R, et al. Impact of an innovative blood factor stewardship program on drug expense and patient care. Am J Health Syst Pharm. 2015 Sep 15;72(18):1579–1584.
   PubMed Web of Science ®Google Scholar
• Concato J, Lawler EV, Lew RA, et al. Observational methods in comparative effectiveness research. Am J Med. 2010;123:e16–e23.
   PubMed Web of Science ®Google Scholar
• Lassila R, Rothschild C, De Moerloose P, et al. The European haemophilia therapy standardisation board. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia. 2005;11:353–359.
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815–825.
   PubMed Web of Science ®Google Scholar
• Mingot-Castellano ME, González-Diaz L, Tamayo-Bermejo R, et al. Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice. Blood Coagul Fibrinolysis. 2015 Jul;26(5):509–514.
   PubMed Web of Science ®Google Scholar
• Björkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8:730–736.
   PubMed Web of Science ®Google Scholar
• Burock S, Meunier F, Lacombe D. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? Eur J Cancer. 2013 Sep;49(13):2777–2783.
   PubMed Web of Science ®Google Scholar
• Health Affairs Blog. 2015. [cited 2016 Apr 11]. Available from: http://healthaffairs.org/blog/2015/04/28/its-time-for-value-based-payment-in-oncology/.
   Google Scholar
• Bardach NS, Wang JJ, De Leon SF, et al. Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA. 2013;310(10):1051–1059.
   PubMed Web of Science ®Google Scholar
• Jha AK, Joynt KE, Orav JE, et al. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med. 2012 Apr 26;366:1606–1615.
   PubMed Web of Science ®Google Scholar